January 31, 2022 The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions
February 8, 2023 TRxA 2023 Funding Opportunities C-Path's Translational Therapeutics Accelerator is a global drug discovery support program...
C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals Critical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By
January 25, 2023 C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform TUCSON, Ariz., Jan. 25, 2023 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Joins PKDOC C-Path is excited to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has joined its Polycy
February 22, 2023 Breaking Down Barriers in Support of Patients with Rare Diseases You’re invited to join C-Path’s Gina Calarco Smith at the upcoming Breaking Down Barriers in Support of Ra
April 9, 2023-April 10, 2023 14th Annual Patient-Reported Outcome Consortium Workshop April 19 – 20, 2023 DoubleTree by Hilton Silver Spring DC North 8777 Georgia Avenue Silver Spring, MD 20910 On April 19–20, 20
April 18, 2023-April 20, 2023 April 18 – 20 | 2023 CDRC Annual Meeting C-Path’s Cure Drug Repurposing Collaboratory will host an in-person, three-day annual Conference and Regulatory Workshop
Regulus Therapeutics Joins PKDOC C-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKD